INTRODUCTION Duloxetine hydrochloride is a dual reuptake inhibitor of both serotonin and norepinephrine. In the present open-label study, the safety of duloxetine at a fixed-dose of 60 mg twice daily (BID) for up to 52 weeks was evaluated and compared to routine care in the therapy of patients diagnosed with diabetic peripheral neuropathic pain (DPNP). METHODS Patients who completed a 13-week...

BACKGROUND Hepatic injury has been reported following duloxetine use. This study further examines the hepatic safety of duloxetine in a large US health insurance database. METHODS In this propensity score-matched cohort analysis in a US commercially insured population (01 August 2004 to 31 December 2010), we compared individuals with depression and without liver disease who initiated duloxeti...

Duloxetine, a dual-reuptake inhibitor of serotonin and norepinephrine, has been approved for the treatment of major depressive disorder and for stress urinary incontinence. We describe a case of a 28 years old male patient with depression with no medical, urogenital, or psychiatric illness histories. He developed severe side effect of urinary retention following 2 weeks of treatment with Duloxe...

To the Editor: There are no published prospective, comparative studies examining the safety of duloxetine in pregnancy, and, to date, there are only 2 case reports describing its use in pregnancy: (1) a 29-year-old woman was treated with duloxetine for depression during the second half of pregnancy and gave birth to a full-term healthy infant,1 and (2) an infant was observed after birth with si...

PURPOSE Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, increases rhabdosphincter contractility via the stimulation of pudendal motor neuron alpha-1 adrenergic and 5-hydroxytryptamine-2 receptors. In this first phase 3 study we assessed the efficacy and safety of duloxetine in women with stress urinary incontinence (SUI). MATERIALS AND METHODS A total of 683 North Ame...

BACKGROUND Anticonvulsants and antidepressants are mostly used in management of painful diabetic neuropathy (PDN). However there are few direct comparisons between drugs of these classes, making evidence-based decision-making in the treatment of painful diabetic neuropathy difficult. OBJECTIVES This study aimed to perform a network meta-analysis and benefit-risk analysis to evaluate the compa...

BACKGROUND The most prominent feature of melancholic depression is a near-total loss of the capacity to derive pleasure from activities or other positive stimuli. Additional symptoms can include psychomotor disturbances, anorexia, excessive guilt, and early awakening from sleep. Melancholic patients may exhibit treatment responses and outcomes that differ from those of non-melancholic patients....

Duloxetine is a relatively balanced selective serotonin and noradrenaline reuptake inhibitor. We report a case of hyponatremia induced by duloxetine developed rapidly after starting the medication in a middle-aged male with multiple somatic symptoms and depression. Two days after discontinuation of duloxetine and management with hypertonic saline as well as fluid restriction, the serum sodium l...

Overactive bladder (OAB) is defined as urgency, usually with frequency and nocturia, and with or without urge incontinence. Duloxetine, an antidepressant that inhibits reuptake of serotonin and norepinephrine, is indicated for the treatment of stress urinary incontinence in Europe. In this paper, we present a case of a 17-year-old female patient with OAB and depressive symptoms who was successf...

Introduction Duloxetine is a combined serotonin and noradrenalin reuptake inhibitor. It is indicated for the treatment of major depressive disorders, diabetic peripheral neuropathic pain in adults and generalised anxiety disorders [1]. It was granted marketing authorisation in 2004 via a Central European Registration Procedure. Tremor and paraestesia are the most common side effects on the CNS....